0000899243-21-007278.txt : 20210218
0000899243-21-007278.hdr.sgml : 20210218
20210218212422
ACCESSION NUMBER: 0000899243-21-007278
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210216
FILED AS OF DATE: 20210218
DATE AS OF CHANGE: 20210218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brenner Malcolm
CENTRAL INDEX KEY: 0001818068
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39409
FILM NUMBER: 21651825
MAIL ADDRESS:
STREET 1: C/O ALLOVIR, INC.
STREET 2: 139 MAIN STREET, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allovir, Inc.
CENTRAL INDEX KEY: 0001754068
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 831971007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 433-2605
MAIL ADDRESS:
STREET 1: 139 MAIN STREET, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ViraCyte, Inc.
DATE OF NAME CHANGE: 20180924
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-16
0
0001754068
Allovir, Inc.
ALVR
0001818068
Brenner Malcolm
C/O ALLOVIR, INC.
139 MAIN STREET, SUITE 500
CAMBRIDGE
MA
02142
1
0
0
0
Common Stock
2021-02-16
4
S
0
5120
41.7518
D
1013543
I
See Footnote
Common Stock
2021-02-16
4
S
0
1000
42.2495
D
1012543
I
See Footnote
Common Stock
2021-02-16
4
S
0
100
43.13
D
1012443
I
See Footnote
Common Stock
2021-02-17
4
S
0
1200
38.6606
D
1011243
I
See Footnote
Common Stock
2021-02-17
4
S
0
1000
39.966
D
1010243
I
See Footnote
Common Stock
2021-02-17
4
S
0
2765
41.2906
D
1007478
I
See Footnote
Common Stock
2021-02-17
4
S
0
200
41.99
D
1007278
I
See Footnote
Common Stock
30197
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.10 to $42.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.10 to $42.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.16 to $39.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.60 to $40.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.89 to $41.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
/s/ Brett Hagen, as Attorney-in-Fact
2021-02-18